Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti CD19 killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapies - Verismo Therapeutics

Next Previous
Drug Profile

Research programme: anti CD19 killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapies - Verismo Therapeutics

Alternative Names: KIR-CAR-19 - Verismo Therapeutics; KIR-CAR-CD19 - Verismo Therapeutics; SynKIR-19

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verismo Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 20 Dec 2024 Verismo Therapeutics has been acquired by HLB Innovation
  • 08 Apr 2024 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 18 Oct 2021 Early research in Haematological malignancies in USA (Parenteral) as of October 2021 (Verismo Therapeutics pipeline; October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top